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BY-NC-ND license (http://creativecomAbstract Radiofrequency ablation (RFA) is a minimally invasive technique, used with ultra-
sound or computed tomography guidance, which can produce tissue coagulation necrosis in
various kinds of tumors in the human body. In the past 10 years, numerous studies about RFA
in benign thyroid nodules have been published. Reviewing these studies, we noticed that the
effectiveness of ablation was higher when it was performed with the “moving-shot technique”
via an internally cooled electrode. A consensus statement published from the Korean Society
of Radiology also suggested the moving-shot technique as a standard ablation procedure for
benign thyroid nodule ablation in Korea. In Taiwan, most symptomatic benign nodules are
currently treatedwith surgical removal. RFA formass lesions is primarily performed for the treat-
ment of metastatic hepatic tumors. In our case, we have attempted to introduce RFA for benign
thyroid nodules in Taiwan. Because endocrinologists in Taiwan were not familiar with this tech-
nique, we adopted a stepwise approach in learning how to perform RFA. We conducted ex vivo
animal ablation exercises to gain experience in setting the radiofrequency generator for the right
ablation mode and appropriate power output. The thyroid nodule volume reduction rate after
1 year of followupwas approximately 50% in this case. Themost important thingwe learned from
this trial is thatwe confirmed the safety of thyroid nodule ablation. To the best of our knowledge,
this is the first reported study of RFA of a thyroid nodule in Taiwan.
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RFA for Benign Thyroid Nodules 33Introduction
Radiofrequency ablation (RFA) is a technique used to
destroy tissues with heat generated from a high-frequency
alternating current. This current is created by a radio-
frequency generator. When the generator is powered on,
the alternating electric current oscillating between 200 kHz
and 1200 kHz in the electrode causes nearby tissue ion
agitation, which can create frictional heat [1]. With that
amount of heat, the electrode can cause target tissue
coagulation necrosis. This technique can be used for abla-
tion of tumors in various kinds of tissue. There are several
commercial vendors making various kinds of ablation sys-
tems, with different generators and electrodes. Some
studies have adopted the Radiofrequency Interstitial Tissue
Ablation Starburst ablation system with hook-expandable
electrodes [2], however, other studies have used the
Radionics Cool-tip ablation system with an internally cooled
electrode [3,4]. In the past 10 years, emerging clinical trials
have examined the efficacy of RFA for benign thyroid nod-
ules. According to published articles, the effectiveness of
these ablations is good, and the average volume reduction
rate is usually more than 50%. The results are even better
when ablation is performed using the “moving-shot abla-
tion” technique [5,6]. Based on a published consensus
statement from the Korean Society of Radiology, this
ablation technique has become a standard procedure in
Korea [7].
The goal of our trial was to introduce this technique in
Taiwan. We adopted the Radionics Cool-tip ablation sys-
tem with an internally cooled electrode and the moving-
shot ablation technique, which targeted benign thyroid
nodules. Our protocol was modified from Jeong et al’s [4]
study. It was approved by the institutional review board of
the Far Eastern Memorial Hospital (FEMH IRB No. 97106)
and the Taiwan Food and Drug Administration. Written
informed consent was also obtained from the patients
prior to the study. For the details of the protocol, please
refer to Table 1; five individualized patients were enrolled
in this study.
Because the training of endocrinologists in Taiwan does
not include RFA techniques, for safety reasons, we suggest
animal ablation practices prior to the ablation trial
involving human patients. In this article, we describe the
process of performing an ex vivo animal ablation study.
Ex vivo animal study and ablation system generator
setting
Pig liver and pig thyroid gland are similar in size to those of
humans, and they make good material for ex vivo animal
studies. Before synthetic thyroid hormones became avail-
able, desiccated thyroid or thyroid extract derived from the
thyroid gland of animals was the primary therapy for pa-
tients with hypothyroidism [8]. Most commercially available
prescriptions of thyroid extract are derived from pigs.
However, after the introduction of synthetic thyroid hor-
mones, demand for pig thyroid glands fell sharply. Nowa-
days, if we need pig thyroid glands, we have to search for a
nearby butchery market. In this trial, we obtained fresh pig
thyroid glands from New Taipei City Butchery Market.The RFA of pig liver has been previously reported in
many studies [9,10]. Most studies evaluated the ablation
volumes under different ablation conditions. In our study,
the purpose of pig liver ablation was not to determine the
ablation efficiency, but to practice doing the moving-shot
technique (Figure 1A). Pig liver is adequately large and
can be placed in a metallic container, which is connected to
the ground pad of the radiofrequency generator. After
inserting the electrode into the tissue and turning on the
generator, coagulation began under the appropriate power
output. Bubbles began to appear and could be seen under
the ultrasound surveillance. We moved the electrode
backward for 3e4 cm, stopped the power output tempo-
rarily, shifted the electrode to another direction, and ab-
lated again. In this way, we learned how to perform the
moving-shot technique with a steady hand.
The next step was pig thyroid gland ablation. Anatomi-
cally, the pig thyroid gland lies over the trachea and is
easily found next to the larynx (Figure 2A). Just like the
human thyroid gland, it is a butterfly-shaped organ,
composed of right, left, and isthmus lobes (Figure 2B). The
pig thyroid gland is much smaller than the pig liver. The
echogenicity of the ex vivo pig thyroid gland is heteroge-
nous and hypoechoic (Figure 2C). In this session, we did not
try to ablate the gland with the moving-shot technique but
attempted to ablate it using a different generator setting.
The Cool tip RF system has two modes for power output: a
manual mode and an impedance mode. Using the imped-
ance mode, the power output will be shut down automat-
ically if the impedance is too high. Using the manual mode
setting and power output at 25 W, microbubbles appeared
2.5 minutes after the ablation began. However, with the
impedance mode setting, microbubbles did not appear
under the power output of 25 W. We increased the power
output to 30 W, and microbubbles were noted at least
3 minutes after the ablation (Figure 2D). In this way, we
demonstrated that the manual mode is better than the
impedance mode in ablating pig thyroid glands. The abla-
tion diameter under a power output of 30 W for 4 minutes
was approximately 1.2 cm (Figure 2E). It is worth pointing
out that some pig thyroid gland capsules ruptured during
ablation when we tried to increase the power output to
50 W with longer ablation times (>5 minutes). This sug-
gested that, although the ablation technique is very safe,
the “safety margin” should be maintained between the
thyroid capsule and the ablation target (Figure 2F).Case report
A 53-year-old woman visited our hospital in 2012 for a left
neck mass with compressive symptoms. She had a history of
a left nodular goiter for 1 year and had been followed
without Levothyroxin suppression therapy. The patient noted
that the nodule had become larger in recent months. She felt
neck discomfort during swallowing upon arrival to our
outpatient clinic. The physical examination revealed a Grade
II goiter on the left lobe of the thyroid. The nodule was
approximately 3 cm in diameter by palpation, relatively soft
in consistency, and was not attached to the adjacent tissue.
Thyroid ultrasonography showed a solid but heterogeneous
nodule in the left lobe. The volume of the nodule was
Table 1 Study protocol.
Patient selection
1. Inclusion criteria
 Presence of subjective symptoms (foreign body sensation, neck discomfort or pain, compressive symptoms).
 A poor surgical candidate or refusal to undergo surgery.
 Fine-needle aspiration cytology (FNAC) showed benign results on two separate occasions.
 Ultrasound (US) findings are compatible with a benign nodule.
2. Exclusion criteria
 FNAC reveals follicular neoplasm or malignancy.
 A nodule with the sonographic criteria for a malignancy (taller than wide, marked hypoechoic, microcalcifications, ill-
defined margins).
 Previous radiation or surgical history to the head and neck.
 Previous sclerosing therapy.
Ablation machine
1. RF generator: Cool-tip RF system (Radionics, Valleylab, Tyco, Boulder, CO, USA)
2. Electrode: an internally cooled Cool-tip electrode (17 gauge, with 1-cm active tip)
Preablation assessment
1. Ultrasound examination
 Record the size, characteristics, composition, intranodular vascularity, and any abnormal lymph nodes in the neck.
 Measure volume of the tumor: V Z pabc/6 (where V denotes volume, a is the largest diameter, and b and c are the other
two perpendicular diameters).
2. Laboratory data
 Thyroid function test: thyroid stimulating hormone (TSH), free thyroxine (FT4), thyroid autoantibodies (TSH-R antibody or
anti-TPO antibody)
 Bleeding tendency: bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT)
 Routine complete blood count (CBC), biochemical tests including renal function test and liver function test
3. Ultrasound-guided fine-needle aspiration cytology (benign results to the same nodule on two separate occasions)
Procedure
1. Place the patient in the supine position with the neck extended.
2. Attach two ground pads in the patient’s both thighs.
3. Local anesthesia with 2% lidocaine at the electrode puncture site (above isthmus).
4. Insert electrode under ultrasound guidance at isthmus (transisthmus approach). The electrode tip will be positioned in the
deepest and most remote portion of the nodule.
5. Power output will begin with 20 W, and will be increased in 5-W increments up to 70 W.
6. When a transient hyperechoic zone appears at the periphery of the nodule, the electrode tip will be moved backward
(moving-shot technique). In the more central area of the nodule, if the transient hyperechoic zone expands around the
electrode tip, the electrode will be moved to an untreated area.
7. Check both thighs frequently to prevent skin burn during ablation.
8. Ablation will be terminated when all units of the nodule have changed to transient hyperechoic zones.
Post-RFA care
1. Let the patient rest for 1 h; then the patient will be observed for any sign of hemorrhage, voice change, or severe local pain.
2. Mild compression at the treatment site will be performed for 10e20 min.
3. Medication: Take oral analgesics (acetaminophen) for 1 d, if necessary.
Post-RFA follow up
 Follow up thyroid function test (Free T4 and TSH).
 Follow up ultrasonography at 1 wk, 1 mo, 3 mo, 6 mo, 9 mo, and 1 y after RFA; record nodule characteristics and volume.
Possible complication management
1. Pain during ablation: Reduce RF power, or stop ablation if severe pain. Medication (acetaminophen) after ablation.
2. Skin burn at electrode puncture site or pad attachment site: ice packing.
3. Voice change: Stop ablation and continue observation for 3 mo.
4. Intrathyroidal/intranodular or extrathyroid hematoma: direct compression and observation.
5. Tracheal thermal injury: Stop ablation and continue observation for 3 mo; surgical repair if necessary.
6. Esophageal thermal injury: Stop ablation and continue observation for 3 mo; surgical repair if necessary.
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Figure 1 Radiofrequency ablation on a pig thyroid gland. (A) Schematic diagram showing the anatomic position of the pig thyroid
gland. (B) Fresh pig thyroid gland, just removed from a slaughtered pig. (C) Ultrasonographic picture of ex vivo pig thyroid gland
showing heterogenous and hypoechoic texture. The inserted electrode could be identified as a bright bold line. (D) Ablation
performed with a power output of 30 W for 3 minutes under manual mode. Hyperechoic bubbles had already developed and could
be seen under ultrasound surveillance. (E) Cross section of pig thyroid gland after fixed-needle ablation, with power output of 30 W
for 4 minutes; ablation diameter, approximately 1.2 cm. (F) Cross section of another pig thyroid gland after ablation showed that
the ablated area went beyond the thyroid capsule.
RFA for Benign Thyroid Nodules 35approximately 6.36 mL (Figure 3A), calculated as VZ pabc/
6 (where V denotes volume, a is the largest diameter, and b
and c are the other two perpendicular diameters). The
preablation sonographic images did not indicate malignancy.
Ultrasound-guided fine-needle aspiration cytology (conduct-
ed twice to the same nodule) was also negative for malig-
nancy or atypical cells. Laboratory examination results
including blood test counts, bleeding time, and routine
biochemistry were all normal. Thyroid functions were normal
as the thyroid stimulating hormone level was 0.42 mIU/mL
(normal range, 0.4e4.0 mIU/mL) and the free thyroxine (FT4)
level was 1.78 ng/dL (normal range, 0.8e2.0 ng/dL). The
thyroid autoantibodies tests produced negative results.We adopted the Cool-tip RF system (Radionics, Valley-
lab, Tyco, Boulder, CO, USA) with an internally cooled
electrode (17 gauge, with 1-cm active tip) as our ablation
tool. The patient was treated with 2% lidocaine for local
anesthesia at the puncture site just above the thyroid
isthmus. The skin was slightly incised to facilitate the
insertion of the electrode. With the guidance of ultraso-
nography, the electrode was inserted into the target nodule
and the electrode tip was positioned at the most remote
portion of the nodule from the isthmus. The ablation mode
was set to the manual mode. We began ablating with 20 W
of power output. In the first 30 seconds, there was no
change at the tip. When we increased the power to 25 W,
Figure 2 Target nodule ultrasonographic pictures prior to, during, and after radiofrequency ablation. (A) Nodule prior to
ablation; estimated volume, 6.36 mL. (B) Nodule during ablation, with transient hyperechoic change. (C) Nodule 1 week after
ablation; estimated volume, 6.30 mL. (D) Nodule 1 month after ablation; estimated volume, 3.91 mL. (E) Nodule 3 months after
ablation; estimated volume, 3.52 mL. (F) Nodule 6 months after ablation; estimated volume, 3.27 mL. (G) Nodule 9 months after
ablation; estimated volume, 2.68 mL. (H) Nodule 1 year after ablation; estimated volume, 3.13 mL.
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Figure 3 Radiofrequency ablation of pig liver. (A) Pig liver placed in a metallic container, ready for practicing the moving-shot
technique. (B) Cross section of pig liver after moving-shot ablation; ablation diameter, about 1 cm.
RFA for Benign Thyroid Nodules 37the formation of a transient hyperechoic zone at the
electrode tip appeared within 10 seconds. The electrode
tip was moved backward slowly to ablate the untreated
area (Figure 3B). Thirty seconds later, a transient hyper-
echoic zone along the needle tract was created after the
electrode tip was moved to the opposite side of the nodule.
Next, we turned off the power, tilted our electrode to
another untreated portion, and inserted the electrode
again to the most remote part of the nodule. Again, we set
the power output to 25 W and another 30 seconds of
ablation was performed. For safety reasons, we did not
ablate the area that was very close to the nodule capsule.
In this way, the moving-shot technique was performed for
eight cycles (Table 2). Seventy percent of the nodular vol-
ume turned hyperechoic, and we discontinued ablation.
The total ablation time was approximately 5 minutes.
During the ablation, the patient could tolerate the proce-
dure well without neck pain or discomfort. After mild
compression for 30 minutes and rest for 60 minutes, the
patient was discharged without any oral analgesics.
We scheduled to follow the patient with ultrasonography
at 1 week, 1 month, 3 months, 6 months, 9 months, and
1 year after ablation to record the nodule characteristics
and volume. The nodule volume at 1 week after ablation
was 6.30 cm3 (Figure 3C), representing 99% of the original
size. The patient did not report any discomfort during that
visit. The serial follow up with thyroid ultrasonography at
1 month, 3 months, 6 months, 9 months, and 1 year showed
that the nodule volumes were 3.91, 3.52, 3.27, 2.68, and
3.13 cm3, respectively (Figures 3D, 3E, 3F, 3G, and 3H). No
complications were noted during the 1-year follow up. The
thyroid function test conducted 3 months after ablationTable 2 Ablation parameters.
Power
(W)
Impedance
(U)
Time
(s)
20 125e127 30
25 124e128 30 Bubbles began to appear
25 130e135 30 Electrode shifted to
another direction
25 125e130 30 Electrode shifted to
another direction
again (8 cycles)
MODE: manual mode. Total ablation time: 5 minutes 0 seconds.yielded normal results, and the thyroid nodule volume
reduction rate was approximately 50%. The test indicated
that the ablation procedure did not affect thyroid function.
Discussion
To the best of our knowledge, this is the first reported study
on the RFA of nodular goiters in Taiwan. Our initial experi-
ence with RFA showed that this is a safe and effective pro-
cedure. The ablation was performed in an outpatient setting
without hospital admission. We confirmed that general
anesthesia was not necessary, and a 2% lidocaine injection at
the electrode puncture site above the isthmus as local
anesthesia was adequate for pain management prior to
ablation. The ablation time was short, and the course of the
moving-shot technique lasted only about 5 minutes. The
power output from the generator was very low (20e25 W).
This means that the patient will not experience much pain
during the ablation. Oral painkillers were totally unnecessary
after the procedure. We just pressed the wound firmly for
30 minutes and recommended bed rest. The course of
postablation follow up was also very smooth. The procedure
did not leave any scar on the patient’s neck. In the post-
ablation 1-month follow-up visit, we could not identify the
electrode puncture site. No side effects, such as voice
change, intrathyroid hematoma, skin burn, and tracheal or
esophageal injury were observed during the 1-year follow
up. The result of ablation was also satisfactory. Prior to
ablation, the volume was 6.30 mL. After the ablation, the
recorded volume was 3.13 cm at the last follow up. The
volume reduction rate was 51%. The neck compressive
symptoms also improved subjectively. The patient was
satisfied with the treatment experience and efficiency. Thus,
we demonstrated that thyroid nodule ablation could be
performed safely and effectively in Taiwan.
RFA for benign thyroid nodules has been shown as an
effective way to reduce thyroid nodule size in many studies
[5,6]. However, to the best of our knowledge, this tech-
nique has not yet been performed in Taiwan. In Taiwan,
most symptomatic benign nodules are treated with surgical
removal [11]. RFA for mass lesions is performed primarily
for the treatment of metastatic hepatic tumors [12].
There are obstacles for an endocrinologist in Taiwan to
perform RFA if patients have thyroid nodules with cosmetic
problems or compressive symptoms. The most important
reason for this is that the training of endocrinologists in
38 M.-T. Lee, C.-Y. WangTaiwan does not include RFA techniques. The preferred
thyroid nodule ablation technique, the moving-shot tech-
nique [13], is even more complicated than the fixed-needle
technique, which is usually performed for hepatoma abla-
tion. To minimize the risk of possible ablation complica-
tions, physicians need stepwise practice prior to performing
ablation in human patients. Our recommendation is that an
ex vivo animal study should be tried first. This allows the
physician to learn how to set the ablation generator, how to
perform the moving-shot technique, and how to precisely
ablate small volume tissue.
In conclusion, RFA has been shown to be a safe and
effective way to ablate thyroid nodules in many trials,
when performed by a well-trained technician. For the
beginner, a stepwise approach to learn how to perform RFA
in thyroid nodules is needed. Ex vivo animal ablation is a
good way to provide an opportunity to practice. The tech-
nician can set the radiofrequency generator for the right
ablation mode and appropriate power output. The physi-
cians can also learn to perform the moving-shot technique
from pig liver ablation. With adequate animal ablation
experience, we can ablate thyroid nodules instead of opt-
ing for invasive surgical intervention in benign nodular
goiters or other metastatic thyroid cancer lesions. The
follow-up course showed that the ablation was very safe
without any significant complications.
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